Recombinant Human Tumor Necrosis Factor alpha/TNFalpha (N-6His)
Produktgrößen
50 µg
£848,00
32-9444-50UG
500 µg
£2102,00
32-9444-500UG
Über dieses Produkt
- SKU:
- 32-9444
- Zusätzliche Namen:
- Tumor Necrosis Factor; Cachectin; TNF-Alpha; Tumor Necrosis Factor Ligand Superfamily Member 2; TNF-a; TNF; TNFA; TNFSF2
- Weitere Details:
- Source : E. coli;Tumor Necrosis Factor--Alpha (TNF--Alpha) is secreted by macrophages; monocytes; neutrophils; T-cells; and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF--Alpha while cells that express CD8 secrete little or no TNF--Alpha. Synthesis of TNF--Alpha can be induced by many different stimuli including interferons; IL2; and GM-CSF. The clinical use of the potent anti-tumor activity of TNF--Alpha has been limited by the proinflammatory side effects such as fever; dose-limiting hypotension; hepatotoxicity; intravascular thrombosis; and hemorrhage. Designing clinically applicable TNF--Alpha mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF--Alpha that binds to murine TNF-R55 but not murine TNF-R7; exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF--Alpha; which binds to both murine TNF receptors. Based on these results; many TNF--Alpha mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF--Alpha High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8; Lys9; Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.
- Versandbedingungen:
- Ambient
- Hersteller:
- Abeomics
- Typ:
- Proteins, Peptides, Small Molecules & Other Biomolecules:Recombinant Proteins
- Datenblatt des Herstellers:download_pdf.php